Related Experiment Video
Updated: Dec 21, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment
Francesco Gatto1, Jens Nielsen2
1Department of Biology and Biological Engineering, Chalmers University of Technology, Göteborg, 41296, Sweden.
Background:
Few exceptional responses in cancer treatment were attributed to a genetic predisposition of the tumor.
Methods:
We analyzed a cohort of 3105 patients from 12 different cancer types and systematically sought the existence of a correlation between overall survival and the interaction of 21 antineoplastic treatments with 6 tumor mutations.
Results:
We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations. The trend could not be attributed to either the treatment or the mutation alone. Univariate and multivariate Cox regression demonstrated that this interaction stood as an independent prognostic predictor of survival.
Conclusion:
Our results suggest infrequent instances of exceptional responses ascribable to tumor genomics yet corroborate the existence of an interaction of temozolomide with IDH1 mutations in lower-grade glioma.
More Related Videos
Related Concept Videos
Cancer
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Comparing the Survival Analysis of Two or More Groups
Treatment Resistant Cancers
Kaplan-Meier Approach

